OncoMatch/Clinical Trials/NCT05850234
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Is NCT05850234 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies AZD0120 for relapsed/refractory multiple myeloma.
Treatment: AZD0120 — This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status of 0 or 1
Prior therapy
Must have received: proteasome inhibitor
Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody
Must have received: immunomodulatory drug
Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody
Must have received: anti-CD38 antibody
Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody
Lab requirements
Blood counts
adequate bone marrow function demonstrated at screening
Kidney function
adequate renal function demonstrated at screening
Liver function
adequate hepatic function demonstrated at screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Birmingham, Alabama
- Research Site · Phoenix, Arizona
- Research Site · La Jolla, California
- Research Site · Los Angeles, California
- Research Site · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05850234 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and immunomodulatory drug.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages